PMID- 23480385
OWN - NLM
STAT- MEDLINE
DCOM- 20140319
LR  - 20181202
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 25
IP  - 1
DP  - 2014 Feb
TI  - MCP-1 in psoriatic patients: effect of biological therapy.
PG  - 83-6
LID - 10.3109/09546634.2013.782091 [doi]
AB  - BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) is a chemokine locally and 
      systemically augmented in psoriasis. A single nucleotide polymorphism in MCP-1 
      promoter region -2518A-->G is associated with higher gene expression. OBJECTIVE: 
      The aim was to evaluate MCP-1 plasma level in psoriatic patients and to relate 
      any association in plasmatic and cutaneous MCP-1 with clinical improvement due to 
      biological drugs. METHODS: Blood samples were obtained from: (i) 30 Caucasian 
      patients with psoriasis and 10 controls, for determining MCP-1 plasma 
      concentrations and -2518A-->G polymorphism occurrence, (ii) 16 psoriatic patients 
      treated by anti-tumor necrosis factor-alpha (TNF-alpha) adalimumab/etanercept or by 
      anti-CD-11 efalizumab, before and after 2 months of treatment. Moreover, biopsies 
      were performed on lesional skin of five patients treated with anti-TNF-alpha. MCP-1 
      plasma concentration and cutaneous expression were determined by ELISA and 
      qRT-PCR. RESULTS: MCP-1 plasma level was significantly increased in psoriatic 
      patients. -2518A-->G polymorphism was similarly distributed in patients and 
      controls and unrelated to MCP-1 plasma level or to Psoriasis Area and Severity 
      Index. All patients receiving biological drugs showed significant clinical 
      improvement. Anti-TNF-alpha therapy moderately reduced MCP-1 plasma concentration and 
      robustly decremented MCP-1 expression in lesional skin. CONCLUSION: MCP-1 should 
      be a potential local inflammatory marker in psoriatic patients to assess disease 
      severity and anti-TNF-alpha treatment efficacy.
FAU - Lembo, Serena
AU  - Lembo S
AD  - Department of Systematic Pathology, Section of Clinical, Allergological and 
      Venereological Dermatology, University of Naples "Federico II" , Italy.
FAU - Capasso, Rosanna
AU  - Capasso R
FAU - Balato, Anna
AU  - Balato A
FAU - Cirillo, Teresa
AU  - Cirillo T
FAU - Flora, Filomena
AU  - Flora F
FAU - Zappia, Vincenzo
AU  - Zappia V
FAU - Balato, Nicola
AU  - Balato N
FAU - Ingrosso, Diego
AU  - Ingrosso D
FAU - Ayala, Fabio
AU  - Ayala F
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunologic Factors)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
RN  - XX2MN88N5D (efalizumab)
SB  - IM
MH  - Adalimumab
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Biomarkers/metabolism
MH  - Case-Control Studies
MH  - Chemokine CCL2/genetics/*metabolism
MH  - Child
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Immunologic Factors/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide/genetics
MH  - Psoriasis/metabolism/pathology/*therapy
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Remission Induction
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
MH  - Young Adult
EDAT- 2013/03/14 06:00
MHDA- 2014/03/22 06:00
CRDT- 2013/03/14 06:00
PHST- 2013/03/14 06:00 [entrez]
PHST- 2013/03/14 06:00 [pubmed]
PHST- 2014/03/22 06:00 [medline]
AID - 10.3109/09546634.2013.782091 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2014 Feb;25(1):83-6. doi: 10.3109/09546634.2013.782091. Epub 
      2013 May 6.